tiprankstipranks
Bassline Productions Inc (BSSP)
OTHER OTC:BSSP
US Market

Bassline Productions (BSSP) Price & Analysis

12 Followers

BSSP Stock Chart & Stats

<$0.01
$0.00(0.00%)
At close: 4:00 PM EST
<$0.01
$0.00(0.00%)

BSSP FAQ

What was Bassline Productions Inc’s price range in the past 12 months?
Currently, no data Available
What is Bassline Productions Inc’s market cap?
Bassline Productions Inc’s market cap is $372.00.
    When is Bassline Productions Inc’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Bassline Productions Inc’s earnings last quarter?
    Currently, no data Available
    Is Bassline Productions Inc overvalued?
    According to Wall Street analysts Bassline Productions Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does Bassline Productions Inc pay dividends?
      Bassline Productions Inc does not currently pay dividends.
      What is Bassline Productions Inc’s EPS estimate?
      Bassline Productions Inc’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Bassline Productions Inc have?
      Bassline Productions Inc has 371,887,000 shares outstanding.
        What happened to Bassline Productions Inc’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Bassline Productions Inc?
        Currently, no hedge funds are holding shares in BSSP
        What is the TipRanks Smart Score and how is it calculated?
        Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

          Company Description

          Bassline Productions Inc

          As of 2021, Baseline Productions, Inc. is actively pursuing opportunities for a merger or acquisition. Simultaneously, the company is working to bring its operations and status up-to-date. This strategic shift follows a significant development on October 9, 2017, when its Pharmaceutical Services Agreement (PSA) with Canteck Pharma, Inc. was terminated. The reason for this termination was the company's inability to secure the necessary licensing to proceed with its immunotherapeutic-based technology, which was specifically targeted at cancer indications, within Mexico.
          Similar Stocks
          Company
          Price & Change
          Follow
          Scinai Immunotherapeutics
          MSP Recovery
          Akanda Corp
          CDT Equity
          Popular Stocks